Compare COTY & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COTY | TLX |
|---|---|---|
| Founded | 1904 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | 2013 | N/A |
| Metric | COTY | TLX |
|---|---|---|
| Price | $3.16 | $7.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | $5.23 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 7.7M | 166.5K |
| Earning Date | 02-05-2026 | 01-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $5,807,300,000.00 | $664,225,558.00 |
| Revenue This Year | $1.75 | N/A |
| Revenue Next Year | $2.33 | N/A |
| P/E Ratio | ★ N/A | $163.23 |
| Revenue Growth | N/A | ★ 55.35 |
| 52 Week Low | $2.94 | $6.87 |
| 52 Week High | $7.10 | $30.36 |
| Indicator | COTY | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 36.78 |
| Support Level | $3.06 | $7.16 |
| Resistance Level | $3.47 | $8.45 |
| Average True Range (ATR) | 0.15 | 0.25 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 38.17 | 5.06 |
Coty is a global beauty maker that generates 65% of sales from prestige beauty products (primarily fragrances) and 35% from mass makeup, skin care, and fragrance. For the fragrance business, Coty licenses luxury and high-end brands including Gucci, Burberry, Hugo Boss, Davidoff, and Calvin Klein. In contrast, its consumer cosmetics business focuses on acquired mass brands such as CoverGirl, Max Factor, Rimmel, Sally Hansen, and Bourjois. It also collaborates with social media celebrity Kylie Jenner to manage makeup products bearing her name. By region, Coty generates close to 48% of sales from Europe, 40% from the Americas, and 12% from Asia-Pacific. German investment firm JAB is a controlling shareholder, with a 54% stake.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.